Commerce Bank Purchases 2,904 Shares of Stryker Co. (NYSE:SYK)

Commerce Bank lifted its position in shares of Stryker Co. (NYSE:SYK) by 1.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 183,427 shares of the medical technology company’s stock after purchasing an additional 2,904 shares during the quarter. Commerce Bank’s holdings in Stryker were worth $66,043,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Morse Asset Management Inc boosted its position in shares of Stryker by 16.5% during the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after purchasing an additional 200 shares in the last quarter. World Investment Advisors LLC boosted its position in shares of Stryker by 126.1% during the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock worth $2,941,000 after purchasing an additional 4,541 shares in the last quarter. Arvest Bank Trust Division acquired a new stake in shares of Stryker in the 3rd quarter valued at about $245,000. Wilmington Savings Fund Society FSB increased its position in Stryker by 13.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock valued at $16,183,000 after buying an additional 5,361 shares in the last quarter. Finally, Tidal Investments LLC raised its stake in Stryker by 13.9% during the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock worth $6,314,000 after buying an additional 2,139 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $346.46 on Friday. The firm’s 50 day moving average is $371.83 and its 200 day moving average is $373.11. The stock has a market capitalization of $132.24 billion, a P/E ratio of 44.65, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm earned $3.46 earnings per share. On average, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

Several analysts recently issued reports on SYK shares. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research report on Monday. Finally, The Goldman Sachs Group set a $422.00 price target on Stryker in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $423.53.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.